Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 310
Report ID: PMRREP32714
Worldwide revenue from the saliva based screening market stands at US$ 320.6 Mn in 2022, with the global market estimated to surge ahead at a CAGR of 7.9% to reach a valuation of US$ 738.5 Mn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Saliva based screening Market Size (2022) |
US$ 320.6 Mn |
|
Projected Market Value (2033) |
US$ 738.5 Mn |
|
Global Market Growth Rate (2023-2033) |
7.9% CAGR |
|
Market Share of Top 5 Countries |
57.0% |
As assessed by Persistence Market Research, saliva based detection kits are expected to hold a largest market share of around 60.2% in 2023. Overall, saliva based screening market sales account for approximately ~1.0% revenue share in the global infectious disease market, which was valued at around US$ 35.5 Bn at the end of 2022.
The global market for saliva based screening recorded a historic CAGR of 6.8% in the last 6 years from 2016 to 2022.
Saliva is non-invasive and simple to collect; saliva has become a viable alternative to serum-based testing over the past ten years. Moreover, the prevalence of numerous disease indicators and biomarkers, including genetic components and proteins, has increased the need for this technology in detecting oral and systemic illnesses.
Saliva testing is a method of measuring fast saliva. Saliva is a valuable diagnostic fluid that accurately detects a person's status; it is utilised as a tool for non-invasive monitoring clinical diagnosis purposes. An oral secretions drug test is another name for a saliva drug test.
Furthermore, because the samples of saliva test are acquired in full sight of the person giving the test, there is no potential of meddling with the sample. Additionally, saliva offers an economical method for screening a bigger population.
A saliva-based diagnosis is also anticipated to be crucial in the early detection of disease, disease monitoring, and progression of systemic & oral diseases as genetic research improves.
Therefore, it is anticipated that increasing use of saliva-based screening will offer profitable potential for market expansion.
The global market is to show higher growth in the coming years at a CAGR of 7.9% and reach a global market size of US$ 738.5 Mn by 2033.
“Innovation in Saliva Based Screening & New Kits is Boosting up the Demand”
To fulfil the growing demand for rapid diagnosis of numerous diseases, innovative new solutions are being developed and introduced. This is one of the key motivators for manufacturers in the worldwide saliva based screening market to step up their game. Innovative new solutions are being developed and introduced to meet the increased demand for the quick detection of many disorders.
This is one of the primary causes of increased producer rivalry in the global market for saliva-based screening. Many well-known and emerging companies are launching new goods or obtaining permits in an effort to increase their market share and sales.
For instance, Good Start Genetics developed VeriYou, a saliva-based screening test for the identification and diagnosis of two common inherited genetic illnesses, including cystic fibrosis (CF) and spinal muscular atrophy, in October 2016. (SMA).
The demand for saliva based screening is increasing in worldwide markets as people become more aware of spread of infectious disease. Manufacturers are trying to release new items on the market and obtain permission for them as a result of the increased approvals of COVID-19 test kits that are practical and easy to use.
The demand for salivary testing is expected to continue to grow as a result of the increasing availability of saliva collection devices, increased preference for non-invasive saliva tests over blood tests for the diagnosis of various diseases, and increased research efforts to adopt technologically advanced products.
For instance, Nalagenetics and Nusantics received regulatory approval to introduce PCR test kits for the detection of COVID-19 in samples of saliva. These kits will serve as an alternative to tests that use swabs from the nose and throat.
“New Entrants in Market is Limiting the Growth”
Other specimens like as blood and nasopharyngeal swabs for detection, are what drive the industry today. Due to the ease with which saliva may be used for both self-detection and clinical purposes, its use is increasing substantially. Despite this, a lot of new businesses are releasing testing kits that use nasal swabs, which is limiting market growth.
However, a number of main challenges, including a lack of the essential knowledge to conduct the tests, a weak network of diagnostic facilities, and a supply of subpar goods, hampers the market for saliva-based testing. However, some of the primary problems impeding the saliva-based testing market include a lack of requisite competence to execute the tests, a weak network of laboratories for diagnosis, and the provision of defective products.
Why is the U.S. Market Booming?
“Growing Technologies in Saliva Based Screening”
The U.S. is set to account for around 28.9% of the global market share for saliva based screening market in 2023.
The American public is concentrating on implementing new technologies for saliva-based early detection of SARS-COV-2 infection.
The U.S. is experiencing profitable development prospects in saliva-based screening due to the rising popularity of self-testing and home-based saliva-based screening. Self-testing home kits are becoming more popular, which can be ascribed to their user-friendliness and availability through a variety of distribution channels including online pharmacies or medicine stores.
Even in rural locations with inadequate healthcare facilities, self-testing kits will become more popular due to their hassle-free operation and mobility. This will increase demand for saliva-based self-screening kits in the upcoming years, coupled with the benefits already outlined.
Why is Germany a Prominent Market for Saliva-based Screening in Europe?
“Increased Use in Saliva based screening”
The Germany market is estimated to hold nearly 10% of the global market value share by 2023, and it is anticipated to increase profitably over the coming years.
Because mutant variations have a high mortality rate, early diagnosis is important for infection management. It can be accomplished by employing rapid test kits. Germany provides significant opportunities for manufacturers to increase their revenue.
The European Medicines Agency (EMA) has given several major companies permission to advertise their products in Germany, which is helping the market for saliva-based screening tests to grow in the country.
What Factors Are Leading to Development of India’s Saliva based screening?
“Increased health has led to adopt Saliva based screening”
The Indian market is anticipated to grow profitably and accelerate to hold about more than 73% market share in 2023, in South Asia, and is expected to grow at a CAGR of 8.5% between 2023 and 2033.
Government and non-profit organisation initiatives in India are increasing public awareness, which is assisting market expansion. Growing public awareness of the importance of early disease diagnosis will boost the nation's market. Self-detection kits are becoming more popular as a way for people to obtain test results with less danger of cross-infection. Future market developments in India may benefit from this.
Which Product is Driving Growth of the Global Market?
“Cost Effective Detection kits”
Saliva based detection kits has held the largest market share of the saliva based screening market in 2022. Saliva based detection kits is further expected to hold a largest market share of 60.2% by 2023
Due to the growing use of COVID-19 saliva-based detection kits, there is a high demand for these products. Saliva based detection kits provide excellent sensitivity and specificity for the SARS-CoV-2 coronavirus detection. Due to widespread knowledge of COVID-19's ability to self-detect, testing is also rising.
For instance, Chembio Diagnostics, Inc. announced the availability of a rapid POCT for COVID-19/Flu A&B test that has been authorised by the U.S. FDA in April 2021.
What are the Prospects for Saliva-Based Screening in Diagnostics?
”Reliable, Accessible, and Affordable Saliva Based Diagnostic Screening”
The diagnostics category dominates the market and is set to account for 77.5% of total revenue in 2023. The rising prevalence of infectious diseases and the availability of improved screening tests are both contributing to the segment's substantial proportion.
Additionally, saliva samples for diagnostic purposes have a number of benefits, such as distinct molecular biomarkers for specific diseases and accessible, affordable, and simple sampling procedure. Additionally, using saliva samples for diagnostic purposes yields reliable, simple-to-use, and portable platforms that aid in the early detection of diseases.
Which End User is Most Preferred for Saliva-based Screening?
“Rise in cases has boosted growth in Hospitals”
The global market is set to be dominated largely by hospitals & clinics with an estimated share of about 49.6% of the global market, in 2023.
As a result of cost-effectiveness improvements for various diagnostic tests brought about by breakthroughs in healthcare systems in countries such as the United States and Japan, more people are making plans for their check-ups and treatment. As a result, hospitals were constantly full to capacity.
Integrated healthcare systems, such as Mount Sinai Health System, for example, initiated the COVID-19 saliva testing programme in April 2021 to protect the public's health once businesses and recreational activities reopened, post COVID-19 lockdown restrictions.
Which Application Offers the Global Market a Profitable Outlook?
“Growing Awareness Regarding Available Saliva based screening”
Infection analysis/detection (non- COVID) sales segment will hold the larger share of about 61.6% in the global market in 2023.
Saliva based screening awareness has increased along with the prevalence of infection detection, creating attractive market expansion potential. Patients' preferences for having direct connections with doctors and pharmacists have served as the main motivating factor.
Kits include the ability to directly and conveniently collect spit into a tube and then add the given reagent, which swiftly lyses both microbial and host cells, and stabilizes the nucleic acid in a single step. The saliva obtained using the saliva collection kits does not require any additional processing.
Considering the efforts made by competitors in the global industry, mergers and acquisitions have emerged as one of the main growth strategies employed by market participants. Numerous international corporations are investing in technology-based research and development to create new products that offer comprehensive solutions to saliva based screening kits.
Key instances include:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the saliva based screening market, which are available in the full report.
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2016-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Key Companies’ Profile |
|
|
Customization & Pricing |
Available upon Request |
Product:
Purpose:
Application:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is currently valued at around US$ 320.6 Mn in 2022.
Sales of the market are set to witness growth at a CAGR of 7.9% over the forecast period.
Demand for the market increased at a 6.8% CAGR from 2016 to 2022.
U.S., Canada, Germany, India & China accounted for the major share in the global market as of year 2022, holding around 57.0% market share.
The U.S. is set to account for around 28.9% of the global market share for saliva based screening market in 2023.
Latin America accounts for around 4.7% share of the global market in 2022.
Japan will hold a market share of about 39.9% of the East Asia saliva based screening market in 2023.
The Germany market is estimated to hold nearly 10% of the global market value share by 2023.
U.K. is estimated to grow at a CAGR of 7.6% over the forecast period.
The Indian market is anticipated to grow profitably and accelerate to hold about more than 73% market share in 2023, in South Asia, and is expected to grow at a CAGR of 8.5% between 2023 and 2033.
